Results 1 to 10 of about 24,320 (267)

Trombocitopenia induzida por heparina [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2001
O objetivo deste relato é fazer uma revisão a fim de obter informações atualizadas sobre trombocitopenia induzida por heparina, suas manifestações clínicas, seu diagnóstico e seu manejo terapêutico.
Fernanda Longhi, Dani Laks, Nelson G.N. Kalil   +2 more
doaj   +5 more sources

Farmacovigilância da heparina no Brasil

Revista Da Associação Médica Brasileira, 2011
ResumoObjetivoInvestigar a origem das preparações de heparina, na forma farmacêutica injetável, disponíveis no mercado brasileiro, discutindo o impacto do perfil dos produtos comercializados e das alterações na monografia da heparina na segurança do fármaco.MétodosPesquisou-se o banco de dados de Produtos Registrados das Empresas de Medicamentos da ...
Edson Perini
exaly   +4 more sources

Heparina [PDF]

Brazilian Journal of Cardiovascular Surgery, 2008
Luís Alberto O. Dallan, Fernando Platania, Adriano M. Milanez   +2 more
doaj   +2 more sources

Trombocitopenia inducida por heparina en dosis profilácticas

Angiologia, 2004
Resumen Introduccion La trombocitopenia inducida por heparina (TIH) es una complicacion poco frecuente, mediada por inmuno-globulinas y no dosisdependiente. La sospecha de TIH secundaria a profilaxis con hepa-rinas raramente se considera, aunque sus complicaciones pueden ser igualmente graves. Caso clinico Varon de 52 anos sometido electivamente
J. Molina, M. Miralles-Hernández
exaly   +2 more sources

Real‐World Experience with a Human Fibrinogen Concentrate: Clinical Data from Adult and Pediatric Patients Requiring Fibrinogen for Bleeding Control and Prevention

The Journal of Clinical Pharmacology, Volume 63, Issue 11, Page 1186-1196, November 2023., 2023
Abstract Human fibrinogen concentrate (Fibryga) received temporary approval for fibrinogen replacement therapy in France (2017), with subsequent full approval for congenital and acquired hypofibrinogenemia. We evaluated real‐world use for on‐demand treatment of bleeding and prophylaxis to enhance our knowledge on fibrinogen concentrate as an option for
Francois Stéphan, Loriane Gutermann, Stéphanie Bourget, Sarah Djabarouti, Johanna Berdugo, Yann Fardini, Pierre Clerson, Guillaume Hébert, Chafké Belmokhtar   +8 more
wiley   +1 more source

Decompressive surgery in cerebral venous sinus thrombosis due to vaccine‐induced immune thrombotic thrombocytopenia

European Journal of Neurology, Volume 30, Issue 5, Page 1335-1345, May 2023., 2023
Abstract Background and purpose Cerebral venous sinus thrombosis due to vaccine‐induced immune thrombotic thrombocytopenia (CVST‐VITT) is an adverse drug reaction occurring after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination.
Katarzyna Krzywicka, Diana Aguiar de Sousa, Charlotte Cordonnier, Felix J. Bode, Thalia S. Field, Dominik Michalski, Johann Pelz, Mona Skjelland, Markus Wiedmann, Julian Zimmermann, Matthias Wittstock, Bruno Zanotti, Alfonso Ciccone, Monica Bandettini di Poggio, Afshin Borhani‐Haghighi, Sophie Chatterton, Avinash Aujayeb, Annemie Devroye, Vanessa Dizonno, Thomas Geeraerts, Fabrizio Giammello, Albrecht Günther, Nasli R. Ichaporia, Timothy Kleinig, Espen S. Kristoffersen, Robin Lemmens, Emmanuel De Maistre, Zahra Mirzaasgari, Jean‐Francois Payen, Jukka Putaala, Marco Petruzzellis, Nicolas Raposo, Elyar Sadeghi‐Hokmabadi, Silvia Schoenenberger, Meenakshisundaram Umaiorubahan, Padmavathy N Sylaja, Anita van de Munckhof, Mayte Sánchez van Kammen, Erik Lindgren, Katarina Jood, Adrian Scutelnic, Mirjam R. Heldner, Sven Poli, Marieke J. H. A. Kruip, Antonio Arauz, Adriana B. Conforto, Sanjith Aaron, Saskia Middeldorp, Turgut Tatlisumak, Marcel Arnold, Jonathan M. Coutinho, José M. Ferro, Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group   +52 more
wiley   +1 more source

Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)

European Journal of Neurology, Volume 28, Issue 12, Page 3925-3937, December 2021., 2021
We retrospectively analyzed data from 6537 predominantly hospitalized COVID‐19 patients registered in the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS) registry between January 2020 and February 2021. Common neurological symptoms were excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular ...
Nina N. Kleineberg, Samuel Knauss, Eileen Gülke, Hans O. Pinnschmidt, Carolin E. M. Jakob, Paul Lingor, Kerstin Hellwig, Achim Berthele, Günter Höglinger, Gereon R. Fink, Matthias Endres, Christian Gerloff, Christine Klein, Melanie Stecher, Annika Y. Classen, Siegbert Rieg, Stefan Borgmann, Frank Hanses, Maria M. Rüthrich, Martin Hower, Lukas Tometten, Martina Haselberger, Christiane Piepel, Uta Merle, Sebastian Dolff, Christian Degenhardt, Björn‐Erik O. Jensen, Maria J. G. T. Vehreschild, Johanna Erber, Christiana Franke, Clemens Warnke, the LEOSS Study Group   +31 more
wiley   +1 more source

Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial

STEM CELLS Translational Medicine, Volume 10, Issue 5, Page 660-673, May 2021., 2021
Abstract Acute respiratory distress syndrome (ARDS) in COVID‐19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti‐inflammatory effects and could yield beneficial effects in COVID‐19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (
Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A. Alvarez, Dimitrios Kouroupis, Ana Alvarez Gil, Raffaella Poggioli, Phillip Ruiz, Antonio C. Marttos, Khemraj Hirani, Crystal A. Bell, Halina Kusack, Lisa Rafkin, David Baidal, Andrew Pastewski, Kunal Gawri, Clarissa Leñero, Alejandro M. A. Mantero, Sarah W. Metalonis, Xiaojing Wang, Luis Roque, Burlett Masters, Norma S. Kenyon, Enrique Ginzburg, Xiumin Xu, Jianming Tan, Arnold I. Caplan, Marilyn K. Glassberg, Rodolfo Alejandro, Camillo Ricordi   +30 more
wiley   +1 more source

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy

Journal of Immunology Research, Volume 2021, Issue 1, 2021., 2021
Liver diseases, including cirrhosis, viral hepatitis, and hepatocellular carcinoma, account for approximately two million annual deaths worldwide. They place a huge burden on the global healthcare systems, compelling researchers to find effective treatment for liver fibrosis‐cirrhosis.
Martín Muñoz-Ortega, Noé Macías-Segura, Javier Ventura-Juárez, Manuel Enrique Ávila-Blanco, Leonardo D. Ponce-Damian, Daniel González-Blas, Esperanza Sánchez-Alemán, Andrés Quintanar-Stephano, Charles Elias Assmann   +8 more
wiley   +1 more source

Avaliação da protamina na neutralização da heparina após circulação extracorpórea [PDF]

Brazilian Journal of Cardiovascular Surgery, 2002
INTRODUÇÃO: A protamina é o antídoto universalmente usado para neutralizar a heparina no final da circulação extracorpórea; porém não existe até o momento consenso sobre uma dose ideal necessária.
Roberto Cardoso BARROSO, José Teles de MENDONÇA, Marcos Ramos CARVALHO, Rika Kakuda COSTA, José Edivaldo dos SANTOS   +4 more
doaj   +1 more source